PharmaTher Holdings Ltd. News Releases

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

Thu, 16 Apr 2026 08:00:00 -0400

Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-generation peptide deliveryToronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed...

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

Mon, 13 Apr 2026 08:00:00 -0400

Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development and commercialization strategyToronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States...

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Thu, 26 Mar 2026 08:00:00 -0400

Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional...

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent entry...

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Mon, 02 Feb 2026 09:27:00 -0500

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering execution,...

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Wed, 14 Jan 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity.PharmaTher's decision to enter...

PharmaTher CEO Publishes Letter to Shareholders

Fri, 02 Jan 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.Dear Shareholders,With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.PharmaTher's strategy is...

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Tue, 02 Dec 2025 09:53:00 -0500

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company.At closing, PharmaTher...

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Mon, 17 Nov 2025 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced that it has entered into an Exclusive Evaluation and Option-to-License Agreement (the "Agreement") with Oakwood Laboratories, LLC ("Oakwood") for the development and commercialization of Oakwood's patented long-acting...

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Fri, 17 Oct 2025 08:26:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a...